New Publications About Bone Marrow Transplant Available for Patients

Publication
Article
OncologyONCOLOGY Vol 12 No 5
Volume 12
Issue 5

Bone marrow transplantation (BMT) is now recognized as standard treatment for many diseases. Patients with cancer, especially those with certain types of leukemia, lymphoma, breast and ovarian cancers, multiple myeloma, and aplastic

Bone marrow transplantation (BMT) is now recognized as standard treatment for many diseases. Patients with cancer, especially those with certain types of leukemia, lymphoma, breast and ovarian cancers, multiple myeloma, and aplastic anemia, increasingly find that a transplant is their best hope for a cure. Interest in this medical procedure has risen tremendously as has the need for information about it.

The National Bone Marrow Transplant Link (nbmtLink) has responded to the increased need for information about BMT. Two publications are now available for patients, family members, and health professionals. They are:

Bone Marrow Transplant Resource Guide—This 25-page booklet provides a complete overview of the transplant process. (Single copies are available to patients at no charge.)

Survivor’s Guide to a Bone Marrow Transplant: What to Expect and How to Get Through It—Written by Keren Stronach, a two-time transplant survivor, this booklet describes the experiences of 25 BMT survivors and offers valuable advice on coping during this period, as well as suggestions on how to prepare for a transplant. (The booklet is available at $9.00 per copy.)

For more information about these publications, contact the nbmtLink office at 800-LINK BMIT (800-546-5268) or call 248-932-8483.

Recent Videos
“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.
Barry Paul, MD, listed cilta-cel, anito-cel, and arlo-cel as 3 of the CAR T-cell therapies with the most promising efficacy in patients with multiple myeloma.
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
Long-term toxicities like infections and secondary primary malignancies remain a concern when sequencing novel agents for those with multiple myeloma.
Management of adverse effects and access to cellular therapies among community oncologists represented key points of discussion in multiple myeloma.
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
Related Content